Advocacy for researchers: advocating for governments and funding
The case of EU-Africa cooperation on health R&D
Identify the priorities and resources: policies, laws, budgets and programmes
Map and engage with the key actors: understand their roles and interactions

Advocacy targets (AU = light blue; EU = dark blue), gateways (pink) and partners (orange)

HRST: AUC department of human resources, science and technology
DSA: AUC department of social affairs
ATM: AUC division on AIDS, TB and Malaria; which host the Secretariat of AWA (AIDS Watch Africa)
ASRIC: African Science, Research and Innovation Council
DG INTPA: Directorate-General for International Partnerships
DG RTD: Directorate-General on Research and Innovation

HRST
DSA
ATM
AWA
ASRIC

AU Commission

HRST
NEPAD/AUDA
AAS
Foundations and other donors

Civil society

European Commission

EU delegations
DG INTPA
DG RTD
Research initiatives (e.g., EDCTP)

European Parliament Committees
In Brussels, we influence the EU political priorities, budgets and legislation.

We do this by engaging with the key EU institutions: Commission, Parliament, Council.

In Addis Ababa and other capitals in Africa we influence the implementation (e.g. action plans, programmes...)

We do this by engaging with EU Delegations there and by mobilising other partners.

Exchange of information & coordination

EU process to programme development cooperation funds:

- EU HQ send instructions to EU Delegations (EUDs)
- EUDs prepare draft indicative plans
- EU HQ and EUDs debate draft indicative plans
- EU Member States validate the programmes
Advocacy activities: partners, messages and impact

UNLEASHING AFRICA’S RESEARCH EXCELLENCE
Maximising Global Health R&I in Africa-EU Development Cooperation

Global health research and innovation (R&I) is critical for Africa’s prosperity

Africa represents roughly 17% of the world’s population. However, it accounts for 25% of the world’s disease burden. Despite this, the continent spends less than 1% of global health spending, makes less than 2% of its medicines and produces less than 1% of global research output. Health and health research are chronically underfunded.

In cooperation with

COVID-19 reminds us of the importance of global health R&I cooperation: AU-EU leadership could now take it to the next level

Monday, February 15, 2021

AHAIC 2021 VIRTUAL CONFERENCE | MARCH 10, 2021
Health R&D for enhanced pandemic resilience, elimination of PRNOS, and attainment of UHC in Africa | 4:20pm - 5:20pm EAT

Tom Karuhi (and Cécile Vernant)

Weeks after the World Health Organization and African leaders issued a global and unprecedented stimulus package of $8 billion, the AU-EU summit declaration, as happened with the AU-EU agenda, with research and disease and ensuring we have the right tools to fight COVID-19.

Erick Achola
Communications and Advocacy Advisor, CHRHealth Project, Amref

Dr Josefa Rono
Co-founder and Managing Partner, E&K Consulting Firm

John Paul Okol
Research and Development Officer, PATH

Imali Ngausa
International Advocacy Officer, Deutsche Stiftung Weltbevölkerung (DSW)

Dr Catherine Kyobutungi
Executive Director, Africa Population and Health Research Center (APHRC)
Thank you.

Agustin Martin Lasanta
Advocacy officer, EU
Deutsche Stiftung Weltbevoelkerung (DSW)
Avenue des Arts 43 | 1040 Brussels | Belgium
agustin.martin@dsw.org
T: +32 483 43 45 88